1228 — Canbridge Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$129.49m
- -HK$13.64m
- CNY78.97m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -218 | -846 | -1,077 | -483 |
Depreciation | ||||
Amortisation | ||||
Non-Cash Items | 97.8 | 629 | 449 | 29.3 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | -9.86 | 47.4 | 25 | 151 |
Change in Accounts Receivable | ||||
Change in Inventories | ||||
Change in Prepaid Expenses | ||||
Change in Accounts Payable | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | -126 | -152 | -587 | -281 |
Capital Expenditures | -42.5 | -153 | -5.33 | -34.8 |
Purchase of Fixed Assets | ||||
Purchase / Acquisition of Intangibles | ||||
Other Investing Cash Flow Items | 0.056 | 0 | 131 | 0 |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Change in Net Intangibles | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | -42.4 | -153 | 126 | -34.8 |
Financing Cash Flow Items | -1.73 | -6.24 | -33.1 | -16.1 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 97 | 679 | 854 | -20.7 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -71.4 | 347 | 385 | -295 |